As of 2025-05-12, the Intrinsic Value of Helix Biopharma Corp (HBP.TO) is -0.93 CAD. This HBP.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.96 CAD, the upside of Helix Biopharma Corp is -196.47%.
Based on its market price of 0.96 CAD and our intrinsic valuation, Helix Biopharma Corp (HBP.TO) is overvalued by 196.47%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -0.93 - -0.93 | -0.93 | -196.47% |
| P/E | (0.01) - (0.06) | (0.02) | -101.9% |
| DDM - Stable | (1.16) - (4.72) | (2.94) | -406.1% |
| DDM - Multi | (0.95) - (3.19) | (1.49) | -254.9% |
| Market Cap (mil) | 50.90 |
| Beta | 0.99 |
| Outstanding shares (mil) | 53.02 |
| Enterprise Value (mil) | 48.90 |
| Market risk premium | 5.10% |
| Cost of Equity | 11.35% |
| Cost of Debt | 5.00% |
| WACC | 7.52% |